Axogen Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Axogen Inc trades at $38.67 (market cap $2.06B), while Consumer Staples Select Sector SPDR Fund trades at $83.95. The key difference: Axogen Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| AXGN | XLP | |
|---|---|---|
Market Cap | $2.06B | — |
Sector | Technology | — |
52-Week High | $46.19 | $90.00 |
52-Week Low | $11.28 | $75.61 |
Enterprise Value | $1.98B | — |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.58, up 0.55% with a bullish technical signal from moving averages. The ETF holds 36 consumer staples stocks and offers a 2.6% dividend yield. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid market uncertainty, with retail sales hitting 12-month highs supporting the sector.
XLP presents a defensive investment opportunity with stable dividend income and low volatility characteristics. The fund's concentrated portfolio of essential consumer goods companies provides resilience during market downturns. Key risks include sector rotation away from defensive stocks and potential margin pressure from inflation. Current technical strength and positive analyst sentiment support near-term upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →